Clinical Trials Browser

Phase 1/2 × capivasertib × 30 days × Clear all

NCT07287917 2026-03-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Phase 1/2 Recruiting

BreastDermatologic

Breast Neoplasms, Melanoma

NCT07294677 2026-03-04

CAVALRY

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma